Treatment for Chronic Focal Ileus
For chronic focal ileus, treatment should be directed at the underlying cause when identifiable, combined with symptom-targeted pharmacological management including prokinetics (prucalopride), antimuscarinics for pain, antibiotics for bacterial overgrowth, and nutritional support with home parenteral nutrition (HPN) when oral/enteral intake is inadequate. 1
Algorithmic Approach to Management
Step 1: Identify and Treat Underlying Conditions
The first priority is addressing any treatable underlying disease 1:
- Connective tissue disorders, enteric myositis, neoplastic disease: May require immunosuppressive therapy (prednisolone, ciclosporin have shown benefit in autoimmune myopathy)
- Diabetes: Optimize control aggressively, potentially with insulin pump
- Electrolyte/endocrine abnormalities: Prevent and correct promptly
- Bacterial overgrowth: Treat with rotating antibiotics (amoxicillin-clavulanic acid, ciprofloxacin, metronidazole, rifaximin) 1
Step 2: Symptom-Targeted Pharmacological Management
The drug therapy targets the patient's most bothersome symptom, even if medications have conflicting actions 1:
For Dysmotility/Constipation:
- Prucalopride (5-HT4 agonist): The preferred prokinetic now that cisapride and tegaserod are withdrawn. Enhances acetylcholine release, improves transit 1
- Linaclotide: Acts on guanylate cyclase-C, increases luminal fluid secretion and accelerates transit, may have visceral analgesic properties 1
- Methylnaltrexone or naloxegol: For opioid-induced constipation specifically, peripherally acting mu-opioid antagonists that don't affect central analgesia 1
- Osmotic laxatives, stimulant suppositories, enemas: Progress from phosphate enemas to high-volume saline washouts or transanal irrigation if needed 1
Critical caveat: Avoid domperidone and metoclopramide for long-term use due to QTc prolongation and tardive dyskinesia risks 1
For Colicky Pain:
- Dietary modification first: Reduce fiber to decrease bacterial fermentation and gas production; consider low FODMAP diet (but avoid in malnourished patients) 1
- Peppermint oil: Simple initial measure 1
- Antimuscarinics:
- Hyoscine butylbromide (poorly absorbed orally; intramuscular preparations more effective for long-term home use)
- Dicycloverine hydrochloride
- Propantheline bromide 1
- Pregabalin, low-dose opioids for severe refractory pain 1
For Vomiting:
- Ondansetron (5-HT3 antagonist): First-line now that domperidone/metoclopramide are contraindicated long-term (note: can worsen constipation) 1
- Venting gastrostomy (≥20 French gauge): If nasogastric drainage helps, consider endoscopic/radiological gastrostomy for decompression. Be aware of complications (leakage, infection) 1
Step 3: Nutritional Support
Home Parenteral Nutrition (HPN) is life-saving and should be initiated when patients cannot meet nutritional requirements orally/enterally 2, 3:
- Grade B recommendation for chronic intestinal failure from non-malignant disease 2
- Consider if unable to tolerate adequate oral intake for >7 days post-operatively 4
- Requires specialized multidisciplinary management and expertise 3
Step 4: Surgical Considerations
Surgery should be highly selective and avoided in most cases 1, 5:
- Avoid colectomy for these patients—outcomes are poor 1
- Defunctioning loop ileostomy (reversible) may be considered before total colectomy 1
- Manual evacuation under anesthesia only if disimpaction fails after oral/rectal treatment 1
- Intestinal transplantation is rescue therapy only for intestinal failure patients unsuitable for or unable to continue HPN 5, 3
Key Pitfalls to Avoid
- Don't use prokinetics after bowel anastomosis 1
- Don't perform colectomy for constipation in dysmotility patients—outcomes are universally poor 1
- Don't use metoclopramide long-term due to irreversible tardive dyskinesia risk, especially in elderly 1
- Don't delay HPN in patients with chronic intestinal failure—it's life-saving, not optional 2, 3
- Don't use restrictive diets (low FODMAP) in already malnourished patients 1
Evidence Quality Note
The evidence base for chronic intestinal dysmotility management is predominantly low quality (case series, expert opinion), with only 12% of literature consisting of controlled studies 3. However, the 2020 Gut guidelines 1 represent the most comprehensive and recent expert consensus, supported by the 2016 ESPEN guidelines on chronic intestinal failure 3.